The most significant reasons for hope and promising advancements for individuals with aniridia, particularly concerning future treatments, vision preservation, and quality of life, as summarised from the 8th EAC.
1. Stem-cell therapies are becoming real, and some are already showing multi-year success
One of the strongest themes was that limbal stem cell deficiency (LSCD) — a major cause of corneal damage in aniridia — is becoming increasingly treatable.
COMET therapy showed meaningful benefit
Professor Yoshinori Oie discussed Cultivated Oral Mucosal Epithelial Transplantation (COMET), where cells from the patient’s mouth are grown and transplanted onto the eye. An aniridia patient in the study had a clear central cornea at one year after treatment.
Even though outcomes can worsen over time due to neovascularisation and opacity, this still demonstrates that:
♦ the diseased corneal surface can potentially be rebuilt,
♦ vision-supporting clarity can be restored,
♦ and regenerative approaches are working in humans.
Moreover, studies being conducted in India with a new technique called SOMET (Simple Oral Mucosal Epithelial Transplantation) hold additional promise for broadening the COMET approach to more hospitals and surgeons that do not have access to special laboratories for growing the patient cells. This will reduce the barriers to accessing the benefits of COMET.
iPSC-derived limbal stem cells may be even more promising
A particularly hopeful development was the induced pluripotent stem cell (iPSC) approach:
♦ scientists in Japan reprogrammed patient-derived cells into stem cells,
♦ differentiated them into limbal-like stem cells,
♦ and transplanted them into patients with LSCD.
The results:
♥ good outcomes at 2 years,
♥ corneas remained clear even at 5 years in follow-up,
♥ and a larger 12-patient multicentre trial is planned in Japan later this year, with a plan to include aniridia patients in that trial.
That is extremely important because long-term durability and immune reactions to stem cell therapy have been major challenges in aniridia-related corneal disease.
2. Personalised medicine for aniridia is becoming realistic
Researchers repeatedly emphasised that they are moving toward:
♦ understanding individual PAX6 mutations,
♦ understanding how different cells behave,
♦ and eventually tailoring therapies to each patient.
This includes:
♦ genomic sequencing,
♦ “multi-omics,”
♦ stem-cell modelling,
♦ and computational mapping of corneal cell behaviour.
The idea that future patients may receive:
♥ their own customised stem-cell therapy,
♥ optimised dosing,
♥ and treatments matched to their exact mutation,
It is one of the most exciting long-term developments.
3. Corneal organoids (“mini corneas”) are accelerating drug development
Researchers created corneal organoids from aniridia patient cells:
♦ tiny lab-grown corneal tissues that mimic real disease.
Why this matters:
♦ scientists can now test therapies directly on “aniridia-like” tissue,
♦ observe potential beneficial or toxic effects of treatment,
♦ and optimise timing and dosage before human trials.
This could dramatically speed up:
♥ therapy screening,
♥ precision medicine,
♥ and understanding why the keratopathy in some patients progresses faster than in others.
4. Read-through drugs like amlexanox are still actively being explored
The summary mentions amlexanox, a “read-through” drug similar in concept to ataluren-like approaches. These therapies aim to help cells bypass certain premature stop mutations in PAX6.
This is hopeful because:
♦ it targets the root genetic problem in about 70% of cases of PAX6 mutation,
♦ it may work without replacing the entire gene,
♦ and organoid systems can now help optimise these therapies.
It suggests the field has not abandoned mutation-correcting pharmacologic therapies
5. Gene therapy is advancing beyond theory
One of the most exciting early-stage concepts was a CRISPR-based PAX6 activation strategy:
♦ instead of editing DNA directly,
♦ researchers are trying to activate the healthy remaining PAX6 copy,
♦ increasing overall PAX6 expression to compensate for deficiency.
Potential advantages:
♥ safer than permanent gene editing,
♥ can be directly delivered to the cornea, and multiple doses can be given to improve the effectiveness
♥ may avoid some risks of traditional CRISPR cutting,
♥ and could potentially be delivered with lipid nanoparticles.
This is still early research, but it represents a significant step toward a true disease-modifying therapy.
6. Glaucoma treatment options are improving
Glaucoma remains a major threat in aniridia, but there were several encouraging updates.
New minimally invasive surgical approaches
The transscleral XEN approach showed:
♦ sustained reduction in intraocular pressure,
♦ and promising early results in aniridia patients.
This matters because traditional glaucoma surgeries in aniridia can be difficult and risky, and XEN is a minimally invasive approach, avoiding disturbing the delicate aniridia eye more than is necessary.
New medication classes
ROCK inhibitors such as netarsudil were discussed:
♥ they improve aqueous outflow by relaxing the trabecular meshwork,
♥ and preservative-free versions may become available.
Preservative-free options are especially important because ocular surface toxicity is such a major issue in aniridia.
7. Simple therapies may meaningfully help the ocular surface now
One surprisingly practical and hopeful point was the discussion of insulin eye drops for treating cornea problems in aniridia.
Reported benefits included:
♦ promoting healing,
♦ reducing inflammation,
♦ easier access and much cheaper and easier to access compared with autologous serum drops,
♦ and good clinical experience with long-term use.
This stands out because it may become a more accessible therapy sooner than advanced gene therapy; however, it provides relief and healing rather than targeting the underlying cause of the keratopathy in aniridia.
Another drug, losartan, given in eye drop form, has shown improvement in keratopathy symptoms in aniridia patients. This drug acts by blocking the process of fibrosis, which can lead to loss of transparency in the cornea. The drug is inexpensive and controlled trials are needed to show it’s benefit in aniridia.
8. Earlier detection and earlier intervention are improving
Several talks emphasised:
♦ detecting AAK early,
♦ screening children carefully,
♦ monitoring nerves and tear function,
♦ and starting protective therapies sooner.
That is hopeful because many complications in aniridia are progressive. Earlier intervention may delay or reduce:
♦ corneal degeneration,
♦ glaucoma damage,
♦ amblyopia,
♦ and ocular surface disease.
9. The field now recognises aniridia as a whole-body condition
Another important shift:
Researchers are increasingly acknowledging that PAX6 affects:
♦ hearing,
♦ smell,
♦ sleep,
♦ metabolism,
♦ neurodevelopment,
♦ anxiety/depression,
♦ and sensory processing.
Why this is hopeful:
♥ patients are being believed,
♥ multidisciplinary care is becoming standard in some places,
♥ the scientific literature is documenting these effects as a reference for families and medical professionals
♥ and support is expanding beyond just “eye care.”
That can dramatically improve the quality of life.
10. International collaboration and patient registries are growing rapidly
This may sound less exciting than stem cells or CRISPR, but it is actually foundational.
The report described:
♦ new registries,
♦ international collaborations,
♦ large patient cohorts,
♦ whole-genome sequencing efforts,
♦ and comprehensive care centres.
Rare diseases often advance slowly because there are too few patients in any one country. These international networks are essential for:
♦ clinical trials,
♦ understanding progression,
♦ and accelerating treatment development.
Overall takeaway
The strongest reason for optimism is that the field appears to be transitioning from:
♥ mostly supportive care,
to:
♥ biologically targeted therapies.
The biggest hopeful areas are:
1. Stem-cell reconstruction of the cornea
2. Gene- and RNA-based therapies targeting PAX6
3. New repurposed pharmacotherapies that can improve the cornea’s status
4. Personalised medicine using patient-derived cells
5. Better glaucoma management
6. Earlier intervention and multidisciplinary care
What stands out most is that multiple approaches are advancing simultaneously:
♦ regenerative medicine,
♦ pharmacologic therapies,
♦ gene activation,
♦ organoid disease modelling,
♦ and improved surgical techniques.
That combination usually signals a field moving from understanding disease to improving patient outcomes.
